# A multidisciplinary approach to the management of disorders of gut-brain interaction: psychopharmacology, psychotherapy, and diet

**Authors:** Francisco J. Barrera Flores, José Adrián Guerrero Tamez, Tatiana Winkelman, Regina Barrera Flores, Elizabeth N. Madva

PMC · DOI: 10.3389/fgstr.2025.1637172 · Frontiers in gastroenterology (Lausanne, Switzerland) · 2026-02-10

## TL;DR

This review explores how combining medications, therapy, and diet can help manage gut-brain interaction disorders like irritable bowel syndrome.

## Contribution

The paper integrates neurophysiological, psychological, and dietary approaches to provide a multidisciplinary treatment framework for DGBI.

## Key findings

- Neuroimaging and genetic studies show emotional and cognitive circuits influence gut sensitivity.
- Anxiety and DGBI are bidirectionally linked, affecting treatment outcomes.
- Brain-gut behavior therapies offer sustained relief and mood benefits comparable to medications.

## Abstract

Disorders of gut-brain interaction (DGBI), including irritable bowel syndrome and functional dyspepsia, are chronic gastrointestinal syndromes characterized by visceral hypersensitivity and altered brain-gut signaling in the absence of known structural pathology. A significant proportion of individuals with DGBI have comorbid psychiatric conditions, especially anxiety and depression, highlighting the biopsychosocial underpinnings of these disorders.

This narrative review synthesizes the neurophysiological, psychological, pharmacological, and psychotherapeutic literature related to DGBI. We examined the role of gut-brain axis dysregulation, the prevalence and impact of psychiatric comorbidity, and evaluated current treatment modalities, including neuromodulators, brain-gut behavior therapies (BGBTs), and dietary interventions.

Neuroimaging and genetic studies support the role of emotional and cognitive circuits in modulating gut sensitivity and symptom perception. Psychiatric comorbidity, particularly anxiety, is bidirectionally linked to DGBI and influences treatment response. Neuromodulators such as tricyclic antidepressants demonstrate modest efficacy. BGBTs—including cognitive behavioral therapy and gut-directed hypnotherapy—exhibit comparable efficacy to pharmacologic treatments, with sustained symptom relief and additional benefit on mood and illness-related beliefs.

DGBI represent complex, stress-sensitive conditions best managed through multidisciplinary care. Integration of pharmacologic neuromodulation, psychotherapeutic interventions, and dietary strategies targeting the brain-gut axis offers the most comprehensive approach. Future research should refine treatment matching based on symptom phenotype, psychological profile, and gut-brain biomarkers to improve long-term outcomes.

## Linked entities

- **Diseases:** irritable bowel syndrome (MONDO:0005052), anxiety (MONDO:0005618), depression (MONDO:0002050)

## Full-text entities

- **Diseases:** functional dyspepsia (MESH:D004415), Disorders of gut (MESH:C536735), Psychiatric comorbidity (MESH:D001523), chronic gastrointestinal syndromes (MESH:D005767), depression (MESH:D003866), interaction (MESH:C563663), visceral hypersensitivity (MESH:D004342), DGBI (MESH:D001927), anxiety (MESH:D001007), irritable bowel syndrome (MESH:D043183)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12885561/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12885561/full.md

## References

105 references — full list in the complete paper: https://tomesphere.com/paper/PMC12885561/full.md

---
Source: https://tomesphere.com/paper/PMC12885561